Evidence map›Paper›PMID 31620434›Full record

ArticleFrontiers in bioengineering and biotechnology2019

Encapsulation and Controlled Release of Resveratrol Within Functionalized Mesoporous Silica Nanoparticles for Prostate Cancer Therapy.

Zanib Chaudhary, Sugarniya Subramaniam, Gul Majid Khan, Muhammad Mustafa Abeer, Zhi Qu, Taskeen Janjua, Tushar Kumeria, Jyotsna Batra, Amirali Popat

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 129 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Drug Delivery Systems for Natural Medicines in Cancer Therapy.Current topics in medicinal chemistry · 2025
    Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Zanib ChaudharySchool of Pharmacy, The University of Queensland, Brisbane, QLD, Australia.
Sugarniya SubramaniamSchool of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia.
Gul Majid KhanDepartment of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan.
Muhammad Mustafa AbeerSchool of Pharmacy, The University of Queensland, Brisbane, QLD, Australia.
Zhi QuSchool of Pharmacy, The University of Queensland, Brisbane, QLD, Australia.
Taskeen JanjuaSchool of Pharmacy, The University of Queensland, Brisbane, QLD, Australia.
Tushar KumeriaSchool of Pharmacy, The University of Queensland, Brisbane, QLD, Australia.
Jyotsna BatraSchool of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia.
Amirali PopatSchool of Pharmacy, The University of Queensland, Brisbane, QLD, Australia.
University of Queensland · AUQuaid-i-Azam University · PKTranslational Research Institute · AUMater Research · AUQueensland University of Technology · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resveratrol (RES) is a naturally existing polyphenol which exhibits anti-oxidant, anti-inflammatory, and anti-cancer properties. In recent years, RES has attracted attention for its synergistic effect with other anti-cancer drugs for the treatment of drug resistant cancers. However, RES faces the issues of poor pharmacokinetics, stability and low solubility which limits its clinical application. In present study, RES has been loaded onto uniformly sized (~60 nm) mesoporous silica nanoparticles (MSNs) to improve its

Indexed as

anti-cancer activitychemotherapymesoporous silica nanoparticlesprostate cancerresveratrol

Identifiers

PMID31620434
PMCPMC6759778
OpenAlexW2971693451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.